Tarsus Pharmaceuticals (TARS) Cash from Financing Activities (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 99.12% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $8.0 million (down 95.6% YoY), while the FY2025 annual figure was $143.4 million, down 7.29% from the prior year.
• Cash from Financing Activities was $1.2 million for Q1 2026 at Tarsus Pharmaceuticals, down from $2.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $136.6 million in Q1 2025 to a low of -$136000.0 in Q3 2022.
• Historically, Cash from Financing Activities has averaged $30.8 million across 5 years, with a median of $2.9 million in 2024.
• Biggest YoY gain for Cash from Financing Activities was 7473300.0% in 2022; the steepest drop was 281.33% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at $264000.0 in 2022, then soared by 7384.85% to $19.8 million in 2023, then tumbled by 85.19% to $2.9 million in 2024, then retreated by 21.01% to $2.3 million in 2025, then sank by 47.92% to $1.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.2 million (Q1 2026), $2.3 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.